DrugPatentWatch Database Preview
Onyx Therap Company Profile
What is the competitive landscape for ONYX THERAP, and when can generic versions of ONYX THERAP drugs launch?
ONYX THERAP has one approved drug.
There are eleven US patents protecting ONYX THERAP drugs.
There are one hundred and seventy patent family members on ONYX THERAP drugs in thirty-six countries and nine supplementary protection certificates in eight countries.
Summary for Onyx Therap
| International Patents: | 170 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for Onyx Therap: | See patent lawsuits for Onyx Therap |
Drugs and US Patents for Onyx Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | 7,737,112 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | 9,511,109 | ➤ Sign Up | ➤ Sign Up | ||||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | 8,207,125 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | 7,417,042 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ONYX THERAP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 60 mg/vial | ➤ Subscribe | 2016-07-20 |
Non-Orange Book US Patents for Onyx Therap
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,198,270 | Compounds for proteasome enzyme inhibition | ➤ Sign Up |
| 8,088,741 | Compounds for enzyme inhibition | ➤ Sign Up |
| 8,324,174 | Compounds for enzyme inhibition | ➤ Sign Up |
| 8,207,124 | Compounds for enzyme inhibition | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Onyx Therap Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 2011148805 | ➤ Sign Up |
| South Korea | 20160033795 | ➤ Sign Up |
| Ukraine | 104600 | ➤ Sign Up |
| New Zealand | 603739 | ➤ Sign Up |
| Spain | 2359004 | ➤ Sign Up |
| Russian Federation | 2615385 | ➤ Sign Up |
| Denmark | 1819353 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Onyx Therap Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2016010,C1781688 | Lithuania | ➤ Sign Up | PRODUCT NAME: KARFILZOMIBAS; REGISTRATION NO/DATE: EU/1/15/1060 20151119 |
| 015 | Luxembourg | ➤ Sign Up | PRODUCT NAME: CARFILZOMIB EVENTUELLEMENT SOUS FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; FIRST REGISTRATION: 20151123 |
| 16/013 | Ireland | ➤ Sign Up | PRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/15/1060 20151119 |
| 0805 | Netherlands | ➤ Sign Up | PRODUCT NAME: CARFILZOMIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/15/1060 20151123 |
| C0017 | France | ➤ Sign Up | PRODUCT NAME: CARFILZOMIB; REGISTRATION NO/DATE: EU/1/15/1060 20151123 |
| 0160008 00189 | Estonia | ➤ Sign Up | PRODUCT NAME: KARFILSOMIIB;REG NO/DATE: EU/1/15/1060 23.11.2015 |
| 2016 00014 | Denmark | ➤ Sign Up | PRODUCT NAME: CARFILZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/15/1060 20151123 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
